In the past week, ABCL stock has gone down by -5.37%, with a monthly decline of -22.99% and a quarterly plunge of -27.70%. The volatility ratio for the week is 5.07%, and the volatility levels for the last 30 days are 4.61% for AbCellera Biologics Inc. The simple moving average for the last 20 days is -11.98% for ABCL stock, with a simple moving average of -28.25% for the last 200 days.
Is It Worth Investing in AbCellera Biologics Inc. (NASDAQ: ABCL) Right Now?
AbCellera Biologics Inc. (NASDAQ: ABCL) has a price-to-earnings ratio of 15.23x that is above its average ratio.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
The public float for ABCL is 203.83M and currently, short sellers hold a 10.88% ratio of that float. The average trading volume of ABCL on March 15, 2023 was 1.78M shares.
ABCL) stock’s latest price update
AbCellera Biologics Inc. (NASDAQ: ABCL)’s stock price has increased by 2.02 compared to its previous closing price of 7.42. However, the company has experienced a -5.37% decline in its stock price over the last five trading sessions. Barron’s reported on 09/17/21 that FDA’s Call on Lilly’s Covid Drug Is Lifting a Partner’s Beaten-Down Stock
Analysts’ Opinion of ABCL
In the past week, ABCL stock has gone down by -5.37%, with a monthly decline of -22.99% and a quarterly plunge of -27.70%. The volatility ratio for the week is 5.07%, and the volatility levels for the last 30 days are 4.61% for AbCellera Biologics Inc. The simple moving average for the last 20 days is -11.98% for ABCL stock, with a simple moving average of -28.25% for the last 200 days.
Analysts’ Opinion of ABCL
Goldman, on the other hand, stated in their research note that they expect to see ABCL reach a price target of $30. The rating they have provided for ABCL stocks is “Buy” according to the report published on December 15th, 2022.
Truist gave a rating of “Buy” to ABCL, setting the target price at $29 in the report published on November 16th of the previous year.
ABCL Trading at -20.89% from the 50-Day Moving Average
After a stumble in the market that brought ABCL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.43% of loss for the given period.
Volatility was left at 4.61%, however, over the last 30 days, the volatility rate increased by 5.07%, as shares sank -22.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.68% lower at present.
During the last 5 trading sessions, ABCL fell by -5.37%, which changed the moving average for the period of 200-days by +0.93% in comparison to the 20-day moving average, which settled at $8.49. In addition, AbCellera Biologics Inc. saw -25.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABCL starting from Thermopylae Holdings Ltd., who purchase 85,102 shares at the price of $10.10 back on Dec 16. After this action, Thermopylae Holdings Ltd. now owns 55,859,493 shares of AbCellera Biologics Inc., valued at $859,249 using the latest closing price.
Thermopylae Holdings Ltd., the 10% Owner of AbCellera Biologics Inc., purchase 200,000 shares at $11.46 during a trade that took place back on Aug 19, which means that Thermopylae Holdings Ltd. is holding 55,844,391 shares at $2,292,460 based on the most recent closing price.
Stock Fundamentals for ABCL
Equity return is now at value 12.90, with 10.10 for asset returns.
Conclusion
In conclusion, AbCellera Biologics Inc. (ABCL) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
